In our pursuit to find a way to improve the therapeutic effect in FD, we considered different agents with the potential to affect IKBKAP. Several potential therapies for FD have been investigated including PS [30–32,34], kinetin [36,37], tocotrienols [47,48], and the green tea component epigallocatechin gallate [49]. This evidence concerns the gene ELP1 and Fabry disease.